Dr. Lal PathLabs Invests Up To ₹30.3 Crore In Wholly Owned Subsidiary PUPL
Mumbai: Dr. Lal PathLabs Limited on Friday announced a further investment in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), by subscribing to equity shares on October 12, 2026. Investment Details The investment involves a cash consideration not exceeding ₹30.3 crore. PUPL will continue to operate as a wholly owned subsidiary of Dr. Lal PathLabs following this transaction.…
Dr. Lal PathLabs announced an investment of up to ₹30.3 crore in its wholly-owned subsidiary, PathLabs Unifiers Private Limited (PUPL), on October 12, 2026. PUPL will remain a wholly-owned subsidiary following this transaction. The funds will be used to buy the remaining 30% stake of CentraPath Labs Private Limited (CPL), making CPL a wholly-owned subsidiary of PUPL.
Dr. Lal PathLabs already holds an 80% stake in Ghana's Sunshine Healthcare subsidiary. PUPL, founded on December 12, 2018, operates in the healthcare and diagnostics sector. The investment is considered a related party transaction, but Dr Lal PathLabs confirmed it was conducted on an arm's length basis.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
